Having watched many of my family members suffer from Alzheimer’s, I am deeply passionate about finding a cure for this debilitating disease. This condition impacts far too many families in North Carolina and across the country and, while treatments have improved, I still remain hopeful that one day we will find a cure.
In order for that to happen, biopharmaceutical companies must have all the tools necessary to continue researching and developing new, cutting-edge therapies. That’s why, as an advocate for biopharmaceutical innovation, I am concerned that last year’s Inflation Reduction Act (IRA) could have a chilling impact on innovation for Alzheimer’s research and development.
The IRA includes harmful price-setting policies for prescription medicines under Medicare. While I understand the intent was to help lower costs, in reality, this kind of government control over medications is misguided and could end up limiting patient access to life-saving treatments. Under the IRA, the government is essentially devaluing medical innovation and forcing biopharmaceutical researchers to make difficult decisions on which disease areas to invest in.